ReviewInternational journal of molecular sciences2025
Role of Regulatory T Cells in Pulmonary Ageing and COPD Development.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Regulatory T cells in perioperative neurocognitive disorders: a systematic review with structured narrative synthesis from molecular mechanisms to clinical translation.Frontiers in molecular neuroscience · 2026Pooled it
- Immunosenescence in Idiopathic Pulmonary Fibrosis.Journal of inflammation research · 2026Review
- Chronic obstructive pulmonary disease reprograms the lung into an immune organ through trained immunity, cell death networks, and immune checkpoint dysregulation.Frontiers in medicine · 2026Article
- Th17/Treg imbalance in inflammatory bowel disease: immunological mechanisms and microbiota-driven regulation.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is recognized as a long-term inflammatory lung condition, predominantly resulting from smoking tobacco. While all smokers exhibit some level of pulmonary inflammation, only about 15-20% go on to develop significant COPD, indicating that specific individual factors may enhance these inflammatory responses and contribute to the disease's progression. T regulatory cell (Treg) activity is crucial in mediating pulmonary inflammation in COPD. With accumulating evidence supporting the autoimmune characteristics of COPD, there has been an increasing focus on the role Treg cells play in the disease's initiation and development. This article aims to review the existing literature regarding Treg cells and their influence on COPD pathogenesis and lung ageing. Treg-mediated suppression is a critical mechanism in the negative regulation of immune-related inflammation, which is significant in various disorders, including autoimmunity, allergies, infections (both acute and chronic), and cancer. The lungs of ageing individuals often resemble those affected by COPD, leading to the perception of COPD as a condition that accelerates lung ageing. Changes in Treg cells with age correspond to decreased adaptive immune responses and a higher likelihood of immune-related disorders. The increased presence of Treg cells in older adults may help explain several immunological conditions commonly associated with ageing, which include malignancies, infections, and COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.